The global hemophilia market is expected to reach USD 18.88 billion by 2028, at a CAGR of 7.72% from 2021 to 2028. Hemophilia is a hereditary disease that is caused by the lack of certain clotting factors, which are essential for the clotting of blood. Hemophilia A accounts for 80% of all hemophilia cases and is caused by the lack of clotting factor VIII.
The increase in the number of product launches and technological advancements, the increased prevalence of hemophilia, and the rise in government initiatives are the major factors that drive the growth of the global hemophilia market. However, the lack of awareness, the high costs of drugs, and the lack of availability of genetic testing are the major factors that impede the growth of the hemophilia market.
The global market is segmented based on product, treatment type, and region. By product, the market is divided into human plasma-derived products, recombinant products, and other products. The recombinant products segment is expected to hold the largest share, owing to the increase in the number of product launches and technological advancements.
Get a comprehensive report summary that describes the market value and forecast along with the research methodology.
By treatment type, the market is divided into on-demand treatment and prophylactic treatment. The prophylactic treatment segment is estimated to generate the highest revenue, owing to its ability to prevent or reduce the severity of bleeding episodes.
By region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA. North America is estimated to dominate the global hemophilia market, due to the presence of better healthcare infrastructure, increased prevalence of hemophilia, and rise in the number of clinical trials.
Key Findings of the Study:
- By region, North America is expected to dominate the market, followed by Europe and Asia-Pacific.
- The key players analyzed in the report are CSL Behring LLC, Novo Nordisk A/S, Pfizer Inc., Shire plc, Bioverativ, Inc., Kedrion S.P.A., Baxalta Incorporated, Octapharma AG, and Grifols S.A.
